Transient Myeloproliferative Disorder Blood Study

AAML08B1: Biology Study of Transient Myeloproliferative Disorder in Children with Down Syndrome

Protocol Description

This Children’s Oncology Group observational study aims to improve understanding of the natural history of transient myeloproliferative disorder (TMD) and its relationship to subsequent leukemia. TMD is found in babies less than three months old with Down syndrome and is caused by abnormal blood cells that travel throughout the body. This research program will facilitate the development of a TMD cell and protein bank and repository of DNA/RNA from megakaryoblasts for future biological studies and to better understand why some TMD cases develop into leukemia and some don’t.

Eligibility Criteria

Subject to certain exclusion criteria, babies of both genders up to 1 year old who have Down syndrome and who were diagnosed with TMD at less than 90 days of age are eligible for this study.
Males: Through 12 months of age
Females: Through 12 months of age


Researchers will collect blood samples over the course of the first 5 years, but only at times when blood is being drawn for standard diagnostic and treatment purposes.
Visits: Not applicable
Duration: 5 years

Status: Open for Enrollment

Source(s) of Support

Children’s Oncology Group (Study AAML08B1)
National Cancer Institute

Primary Investigator

A. KIm Ritchey, MD

Contact Information

For additional information, please contact:
Jill Visnich